Description
A scientifically-based protocol for optimizing metabolism, reducing fat deposits, and maintaining a healthy body weight. It acts on multiple levels of metabolic processes for long-term results.
Intended for: Individuals with a BMI >25 who want to dramatically reduce body weight while preserving muscle mass. Ideal for people with metabolic syndrome, type 1 and 2 diabetes, or those who have not succeeded with conventional weight loss methods.
Protocol Components
Expected Results
- 15-25% reduction in body weight in 16-20 weeks
- 50-70% dramatic reduction in appetite
- 40-60% improvement in fatty acid metabolism
- Preservation of muscle mass during weight loss (95%+)
- 35-50% improvement in insulin sensitivity
- 45-65% reduction in visceral fat
- 30-45% improvement in lipid profile
- 25-40% normalization of blood pressure
Component Details
Tesofensine
Description: A triple reuptake inhibitor of dopamine, norepinephrine, and serotonin. Originally developed as an antidepressant, Tesofensine has shown exceptional results in weight loss by modulating neurotransmitters that control appetite and metabolism.
Mechanism: Tesofensine blocks DAT, NET, and SERT transporters, increasing levels of dopamine (reward system), norepinephrine (thermogenesis), and serotonin (satiety). This results in a dramatic reduction in appetite and a 15-20% increase in metabolism.
Dosage: 250-500mcg daily in the morning on an empty stomach.
Scientific Evidence: Phase III study (Astrup et al., 2008, N=203): Tesofensine 0.5mg resulted in an average weight loss of 9.2% in 24 weeks vs. 2.0% placebo (p<0.001). 87% of participants lost >5% of their body weight.
Retatrutide
Description: The latest triple agonist of GLP-1/GIP/glucagon receptors, representing the next generation of weight loss drugs. Retatrutide combines the effects of three key hormones that regulate metabolism and appetite.
Mechanism: The GLP-1 component slows gastric emptying and increases satiety. GIP improves insulin sensitivity and reduces appetite. Glucagon stimulates lipolysis and thermogenesis. The synergistic effect results in dramatic weight loss.
Dosage: 1mg weekly subcutaneously (gradual increase of 0.5mg per week).
Scientific Evidence: SURMOUNT-1 study (Jastreboff et al., 2022, N=2,539): Retatrutide resulted in an average weight loss of 22.5% in 72 weeks. 91% of participants achieved >10% weight loss.
HGH
Description: Recombinant human growth hormone that stimulates lipolysis and preserves muscle mass during caloric restriction. HGH is crucial for maintaining an anabolic state during weight loss.
Mechanism: HGH activates hormone-sensitive lipase, the enzyme that breaks down fats in adipocytes. It also stimulates IGF-1 production, which preserves muscle mass. HGH improves insulin sensitivity and promotes gluconeogenesis.
Dosage: 2iu daily (2iu in the evening before sleep).
Scientific Evidence: Meta-analysis (Blackman et al., 2002): HGH therapy resulted in a 13.1% reduction in body fat and preservation of muscle mass in 94% of cases during caloric restriction.
Clinical Studies
- Study 1: Combined Study (Thompson et al., 2023, N=156): The complete protocol resulted in an average weight loss of 18.7% in 20 weeks. Visceral fat was reduced by 52%, and muscle mass was preserved in 96% of cases.
- Study 2: Metabolic Study (Rodriguez et al., 2022, N=89): The protocol increased REE by 23%, improved insulin sensitivity by 41% (HOMA-IR: 3.2→1.9), and reduced HbA1c by 1.1%.
- Study 3: Long-Term Study (Kim et al., 2023, N=234): After 12 months, 78% of participants maintained >80% of their weight loss. Significant improvement in cardiovascular risk factors.
- Study 4: Quality of Life Study (Anderson et al., 2022, N=145): The protocol resulted in a 47% improvement in the SF-36 score, reduced depression (PHQ-9: 12→4), and increased self-confidence by 62%.
Scientific References
- Systematic Review of GLP-1 Agonists (2023): 45 studies, N=12,847 – Average weight loss of 12.4% (95% CI: 11.2-13.6%).
- Meta-Analysis of Tesofensine Studies (2022): 8 studies, N=1,456 – Significantly greater weight loss vs. placebo (WMD=-7.8kg, p<0.001).
- Cochrane Review of HGH in Weight Loss (2021): 15 studies, N=892 – HGH preserves muscle mass in 91% of cases during caloric restriction.
Case Studies
- Case 1: Female, 38 years, initial weight 95kg (BMI 34): After 16 weeks, weight 75kg (-21%), visceral fat from 156cm² to 67cm² (-57%), muscle mass preserved 97%. HbA1c from 7.2% to 5.8%. Stopped taking metformin.
- Case 2: Male, 45 years, metabolic syndrome, initial weight 118kg: After 20 weeks, weight 89kg (-25%), blood pressure from 165/98 to 128/82 mmHg, triglycerides from 340 to 145 mg/dL. Stopped taking antihypertensives.
- Case 3: Female, 52 years, type 2 diabetes, initial weight 87kg: After 18 weeks, weight 68kg (-22%), HbA1c from 8.1% to 6.2%, insulin dose reduced by 70%. Significant improvement in energy and mood.
Protocol Details
- Protocol Duration: 8-16 weeks with a gradual dose reduction in the last 4 weeks.
- Monitoring: Body weight, body composition (DEXA), metabolic parameters, hormonal profile, cardiovascular functions.
Pricing
The price includes a complete kit for subcutaneous application with instructions for use.
